Industry Trends: The Move to Preferred Networks

Major PBMs are moving toward creating alternative pharmacy networks by moving out one major retail chain (such as CVS or Walgreens) from their in-network coverage. The...

Drug Information Update- Ingrezza (valbenazine)

Ingrezza (valbenazine) New Drug Approval: On April 11 th , 2017, the FDA approved Ingrezza (valbenazine) for the treatment of adults with tardive...

Examining Drug Trend: Diabetes

Drug price is driving trend. Overall utilization for the top 10 drug classes in 2016 decreased, while prices increased. To better understand 2016 trend, we will be...

Drug Information Update- Dupixent (dupilumab)

Dupixent (dupilumab) New Drug Approval: On March 13 th , 2017 the FDA approved Dupixent (dupilumab) for the treatment of adult patients with...

Drug Information Update- Ocrevus (ocrelizumab)

Ocrevus (ocrelizumab) New Drug Approval: On March 28 th , 2017 the FDA approved Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of...

Drug Information Update- Kisqali (ribociclib)

Kisqali (ribociclib) New Drug Approval: On March 13 th , 2017 the FDA approved Kisqali (ribociclib) in combination with an aromatase inhibitor as initial...

Drug Inflation in the News: EpiPen

With drug inflation at the forefront of trend concerns in the pharmacy benefit industry, the rise in cost of drugs like the EpiPen have gained lots of press coverage in...

How Blockbuster Drugs are Shaping Drug Inflation

With the cost of certain medications rising rapidly, it’s no surprise that many plan sponsors are feeling the financial impact of price increases associated with drug...

5 Reasons You Won’t Want to Miss The MedImpact Annual Conference

  The MedImpact conference is only 5 weeks away! Don’t miss out on the opportunity to hear from industry experts on all the hot topics affecting...

Biosimilars: The Challenges and The Opportunities

Biosimilar drugs present a large potential for reducing specialty spending, but their instability and sensitivity to manufacturing present challenges as well. Biosimilars...

Drug Information Update- Basaglar (insulin glargine)

New Drug Approval - Basaglar (insulin glargine) FDA Approval: In December 2015, the FDA approved Basaglar (insulin glargine), a long-acting human insulin...

Combating Opioid Waste and Abuse

Opioids are now the leading cause of accidental death in the U.S . According to the Center for Disease Control (CDC), there were a total of 47,055 lethal drug overdoses...

Drug Information Update- Inflectra (infliximab-dyyb)

New Drug Approval: Inflectra (infliximab-dyyb) FDA Approval: On April 5 th , 2016 the FDA approved Inflectra (infliximab-dyyb) for Crohn’s disease...

Drug Information Update- Amjevita (adalimumab-atto)

New Drug Approval: On September 23 rd , 2016 the FDA approved Amjevita (adalimumab-atto), a biosimilar for Humira, for rheumatoid arthritis (RA), psoriatic...

Drug Information Update- Exondys 51 (eteplirsen)

New Drug Approval: On September 19 th , 2016 the FDA approved Exondys 51 (eteplirsen) for the treatment of Duchenne Muscular Dystrophy (DMD) in patients who...

The 2015 Annual Trend Report is Here

MedImpact has released its 2015 Annual Trend Report. The purpose of this report is to provide a better understanding of the proactive strategies and solutions we can help...

MedMatters

Latest announcements and news from MedImpact. Updated December 2015.

Clinical Pipeline® Report Discusses Impact on Drug Benefits

Soon-to-be-released drugs and biologicals in the development pipeline may significantly impact medication cost, utilization and insurance benefit coverage. Comprehensive understanding of the...